Skip to content
Peptideworth

Peptide guide

BPC-157: What the Evidence Actually Shows

Also calledBody Protection Compound-157PL 14736Pentadecapeptide BPC 157

BPC-157 is one of the most-searched peptides on the market, and one of the least tested in people. The healing claims come from a large, fairly consistent body of rodent research. What follows that research into human use is a regulatory gray zone, not a clinical trial. Here is what the animal data actually shows, what is proposed to explain it, and what a reader should not assume from either.

By Grant Delaney, Research Editor
Top phase

Preclinical

Human RCTs

0

FDA approval

None

503A status

Restricted

Compound

What it is

BPC-157 is a synthetic 15-amino-acid peptide built to match a fragment of a protein found in human gastric juice. It is not extracted from anything — what ships from a research-chemical seller is a lab-synthesized copy of that sequence, sold as an injectable or oral solution.1

Mechanism

How it works

Rodent studies propose that BPC-157 promotes new blood vessel growth toward damaged tissue and interacts with several growth-factor and nitric-oxide signaling pathways involved in wound repair. That mechanism is what the tendon-, muscle-, and gut-healing results are attributed to, though the exact receptor it acts through has not been settled.1,2

Evidence

What the trials found

Animal only

Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

A 2019 review of the musculoskeletal literature found BPC-157 accelerated healing across dozens of rodent tendon, ligament, and muscle-injury experiments, with a similarly consistent pattern in earlier rat models of gut ulceration. Every one of those experiments was conducted in animals — the review identified no completed randomized controlled trial testing BPC-157 against an outcome in a person.2

15amino acids

Peptide length

A synthetic sequence matching a fragment found in human gastric juice.

Randomized controlled trials in humans

None completed, per a 2019 review of the musculoskeletal literature.

Human dose-ranging study

None exists — online doses are scaled from rodent body weight, not validated in people.

Controlled human safety data

A 2026 review found favorable animal safety signals but little controlled human data.

Human evidence, by study type

Rodent/animal studies
No data
Human randomized trials
0 studies
How to read the evidence meter

How to read the evidence meter

Four steps, weakest to strongest. Most peptides sold for a goal light up one. We show the step the published human evidence actually reaches — not the step the seller implies.

  1. AnecdotalUser reports and forum consensus. No controlled data.
  2. Animal onlyRodent or cell studies. Nothing published in humans.
  3. Early humanSmall, open-label, or phase 1/2 trials. Promising, unproven.
  4. Randomized trialsRandomized controlled trials in humans, at scale.

Timeline

Development pipeline

  1. 1Current step

    Preclinical

    Where the evidence currently sits — rodent tendon, ligament, muscle, and gut-injury models

  2. 2Not reached

    Phase 1

  3. 3Not reached

    Phase 2

  4. 4Not reached

    Phase 3

  5. 5Not reached

    FDA review & approval

    Also absent from the 503A bulk-substances list

Summary

What the evidence does — and doesn't — support

Not yet tested in humans

A 2019 review of the musculoskeletal literature covering BPC-157's tendon, ligament, and muscle studies identified no completed randomized controlled trial testing it against an outcome in a person.
What the evidence supports
  • Accelerated healing across many rodent tendon, ligament, and muscle-injury studies
  • A consistent healing pattern in earlier rat models of gut ulceration
  • A proposed mechanism — new blood-vessel growth and growth-factor/nitric-oxide signaling — that would explain the animal results
What it does not support
  • Tendon, muscle, or gut healing in a human being — no completed trial has tested this
  • Any specific human dose — nothing published derives one from a person
  • Long-term human safety — controlled human safety data is essentially absent
Show 1 more
  • Purity or identity of what is actually sold — this category carries no batch verification

Reality check

The catch

The entire healing story is built on rodent data. Nothing published shows BPC-157 heals a tendon, a muscle, or a gut lesion in a human being, and a 2026 review of unapproved peptide therapies groups it with compounds sold direct to patients without the human safety or efficacy data a real drug approval requires. It is also not on the FDA's list of bulk substances a compounding pharmacy may legally use, so a compliant pharmacy will not sell it — what circulates is unregulated research-chemical stock, not a verified pharmaceutical product.

Dosing

Dosing evidence

There is no human dose-ranging or pharmacokinetic study to derive a dose from. The milligram amounts and injection schedules circulating on forums and seller sites are scaled down from rodent doses by body weight, which is not how a human dose normally gets established, and none of those extrapolated doses has been tested against an outcome in a person.1

Already have a dose in mind? Our reconstitution calculator converts it to syringe units. It does not suggest one.

Safety

Safety and side effects

Human safety data is thin. The 2026 review of unapproved peptide therapies lists BPC-157 among compounds with favorable animal safety signals but little controlled human safety data, and notes that peptides sold in this category typically carry no batch-purity verification of the kind a pharmaceutical product would.3

Under active FDA restriction — compliant pharmacies decline to sell it.

Why "from gastric juice" is misleading

BPC-157 is routinely described as derived from a protein in human gastric juice, which makes it sound like a digestive compound your body already produces. What is actually sold is a synthetic peptide built to that amino-acid sequence in a lab — a stomach has never produced a vial of it 1.

Full analysis — 2 more sectionsWhat the animal literature actually supports · Where the regulatory status leaves a buyer

What the animal literature actually supports

The rodent results are real and reasonably consistent across tendon, ligament, muscle, and gut-injury models 2. That is also the ceiling of what has been shown: extending a rodent healing result to a person is an assumption, not a conclusion the studies themselves make.

Where the regulatory status leaves a buyer

BPC-157 is not on the FDA's list of bulk substances a compounding pharmacy may legally use under Section 503A, so a pharmacy trying to stay compliant will decline to sell it. What is available instead is labeled for research use, without the purity verification a real medicine carries 3.

Questions

Frequently asked questions

Has BPC-157 been tested in humans?

Not in a completed randomized controlled trial. The healing effects it is sold for — tendon, ligament, muscle, and gut repair — come entirely from rodent studies. No published human trial has measured whether it produces the same result in a person.

Is BPC-157 legal to buy?

It is not FDA-approved as a drug, and it is not on the FDA's list of substances a compounding pharmacy may legally use, so a compliant pharmacy will not sell it to you. It is sold instead as a research chemical, which is a legal category describing what a seller may ship without a prescription — not a safety or quality standard.

What dose of BPC-157 is effective?

There is no human dosing study to answer that from. Doses seen online are scaled down from rodent studies by body weight, which has never been validated as a way to dose a person, and no such dose has been tested against a human outcome.

Glossary

Key terms

Show definitions
Rodent model
An animal study used to test a compound's biological effect before — and separately from — any human trial.
Randomized controlled trial (RCT)
A study that randomly assigns participants to treatment or control — the standard human evidence a drug approval is built on.
Section 503A
The part of federal law under which a compounding pharmacy may prepare a drug from bulk ingredients — only for substances on the FDA's approved bulk-substances list.
Research chemical
A legal sales category for substances shipped as laboratory material rather than as a medicine — it describes what a seller may ship, not a safety or purity standard.
Pharmacokinetic study
Research measuring how a compound is absorbed, distributed, and cleared by the body — the basis for establishing a human dose.

Sources

References

Show all 3 sources
  1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). https://pubmed.ncbi.nlm.nih.gov/40005999/
  2. Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. https://pubmed.ncbi.nlm.nih.gov/30915550/
  3. Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.